Correspondence 0001493152-23-022609 from Aridis Pharmaceuticals, Inc. (ARDS) (CIK 0001614067)
Aridis Pharmaceuticals, Inc. (ARDS) (CIK 0001614067)
Date: June 27, 2023 · CIK: 0001614067 · Accession: 0001493152-23-022609
AI Filing Summary & Sentiment
File numbers found in text: 333-272128
Letter
Sheppard, Mullin, Richter & Hampton LLP
Rockefeller Plaza
New York, New York 10112-0015
212.653.8700 main
212.653.8701 fax
www.sheppardmullin.com
VIA EDGAR
June 27, 2023
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Attention: Dillon Hagius
Laura Crotty
Re: Aridis Pharmaceuticals, Inc.
Amendment No. 1 to Registration Statement on Form S-1
Filed June 9, 2023
File No. 333-272128
Ladies and Gentlemen:
This letter sets forth the responses of Aridis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), to the comments received from the Staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) concerning its Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-272128) filed with the Commission on June 9, 2023 (the “Registration Statement”).
References in the text of the responses herein to captions and page numbers refer to Amendment No. 2 to the Company’s Registration Statement on Form S-1 (the “Amended Registration Statement”), which is being filed herewith.
Amendment No. 1 to Registration Statement on Form S-1
Cover Page
1. Given that this is a best-efforts, no minimum, and self-underwritten offering in which you are not required to arrange for the purchase and sale of any specific number or dollar amount of shares and that you may not sell the entire amount of common stock and warrants being offered, please delete the reference to the total amount of proceeds you may receive from the offering in the header on the cover page. Additionally, when known, please revise the header to quantify the number of shares underlying the warrants and prefunded warrants.
RESPONSE:
The Company respectfully acknowledges the Staff’s comment and has deleted the reference to the total amount of proceeds in the header on the cover page and added in the number of shares underlying the warrants and prefunded warrants.
*****
If any additional supplemental information is required by the Staff or if you have any questions regarding the foregoing, please contact Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP at (212) 634-3067 with any questions or further comments regarding the responses to the Staff’s comments.
Very
truly yours,
/s/
Jeffrey Fessler
Show Raw Text
CORRESP
1
filename1.htm
Sheppard,
Mullin, Richter & Hampton LLP
30
Rockefeller Plaza
New
York, New York 10112-0015
212.653.8700
main
212.653.8701
fax
www.sheppardmullin.com
VIA EDGAR
June
27, 2023
United
States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington,
D.C. 20549
Attention: Dillon
Hagius
Laura
Crotty
Re: Aridis
Pharmaceuticals, Inc.
Amendment No. 1 to Registration Statement on Form S-1
Filed June 9, 2023
File No. 333-272128
Ladies
and Gentlemen:
This
letter sets forth the responses of Aridis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), to the comments
received from the Staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”)
concerning its Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-272128) filed with the Commission on June 9, 2023
(the “Registration Statement”).
References
in the text of the responses herein to captions and page numbers refer to Amendment No. 2 to the Company’s Registration Statement
on Form S-1 (the “Amended Registration Statement”), which is being filed herewith.
Amendment
No. 1 to Registration Statement on Form S-1
Cover
Page
1.
Given that this is a best-efforts, no minimum, and self-underwritten offering in which you are not required to arrange for the purchase
and sale of any specific number or dollar amount of shares and that you may not sell the entire amount of common stock and warrants being
offered, please delete the reference to the total amount of proceeds you may receive from the offering in the header on the cover page.
Additionally, when known, please revise the header to quantify the number of shares underlying the warrants and prefunded warrants.
RESPONSE:
The
Company respectfully acknowledges the Staff’s comment and has deleted the reference to the total amount of proceeds in the header
on the cover page and added in the number of shares underlying the warrants and prefunded warrants.
*****
If
any additional supplemental information is required by the Staff or if you have any questions regarding the foregoing, please contact
Jeffrey Fessler of Sheppard, Mullin, Richter & Hampton LLP at (212) 634-3067 with any questions or further comments regarding the
responses to the Staff’s comments.
Very
truly yours,
/s/
Jeffrey Fessler
Sheppard,
Mullin, Richter & Hampton LLP
cc:
Vu Truong, Chief Executive Officer
2